September 2024

SHANGHAI, Sept. 26, 2024 /PRNewswire/ — BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 has been granted the Breakthrough Therapy Designation (BTD) by National Medical Products Administration (NMPA) for the treatment of IgA nephropathy (I

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: